IOBT实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Stats
今日成交量	38 770.00
平均成交量	139 158
市值	97.50M
EPS	$0 ( 2024-03-12 )
下一个收益日期	( $-0.370 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.750
ATR14	$0.0120 (0.81%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Zocca Mai-britt	Buy	750 000	Stock Option (Right to Buy)
2024-03-15	Sullivan Amy	Buy	280 000	Stock Option (Right to Buy)
2024-03-15	Smith Devin Whittemore	Buy	185 000	Stock Option (Right to Buy)
2024-03-15	Burkavage Brian	Buy	50 000	Stock Option (Right to Buy)
2024-03-15	Ahmad Qasim Iftikhar	Buy	280 000	Stock Option (Right to Buy)

INSIDER POWER
96.12
Last 87 transactions
Buy: 67 695 200 \| Sell: 7 604 578

音量相关性

長: 0.14 (neutral)

短: -0.81 (strong negative)

Signal:(30.844) Neutral

IO Biotech, Inc. 相关性

10 最正相关
PTRA	0.957
FRST	0.952
SGMO	0.951
MOFG	0.95
SMBC	0.944
SPFI	0.943
CBAN	0.942
ABCB	0.941
ALTO	0.941
FMBH	0.94

10 最负相关
RMRM	-0.922
DRNA	-0.906
SGEN	-0.889
RPHM	-0.884
BLPH	-0.881
EBACU	-0.88
TZPS	-0.88
ALDX	-0.879
KBAL	-0.879
MLAI	-0.879

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

IO Biotech, Inc. 相关性 - 货币/商品

-0.51
( weak negative )

-0.04
( neutral )

0.00
( neutral )

-0.55
( weak negative )

0.07
( neutral )

-0.45
( neutral )

IO Biotech, Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$-756 000 (0.00 %)
EPS:	$-1.980

FY	2023
营收:	$0
毛利润:	$-756 000 (0.00 %)
EPS:	$-1.980

FY	2022
营收:	$0
毛利润:	$-540 000 (0.00 %)
EPS:	$-2.48

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-15.51

Financial Reports:

No articles found.

IO Biotech, Inc.

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.